Logos Global Management LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1792126) · Explore on the interactive board
Logos Global Management LP disclosed 68 US equity positions worth $2.3bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ERAS at 9.6% of the reported book, followed by ABVX, RVMD. The top ten holdings are 48.3% of the book, and the portfolio behaves like about 29 equal-weight positions. Versus the prior filing it opened 25 new positions, added to 18, reduced 19 and exited 20. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Logos Global Management LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 25 new, 18 added, 19 reduced, 20 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ERAS ERASCA INC | Healthcare | 9.6% | $222.6m | 12,150,000 | 9% | added |
| 2 | ABVX ABIVAX SA | Healthcare | 5.9% | $136.5m | 1,024,000 | 52% | added |
| 3 | RVMD REVOLUTION MEDICINES INC | Healthcare | 5.6% | $131.1m | 700,000 | -65% | reduced |
| 4 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 4.8% | $111.8m | 3,000,000 | -13% | reduced |
| 5 | BNTX BIONTECH SE | Healthcare | 4.1% | $94.4m | 1,015,000 | – | new |
| 6 | VERA VERA THERAPEUTICS INC | Healthcare | 4.1% | $94.4m | 2,200,000 | – | new |
| 7 | TNGX TANGO THERAPEUTICS INC | Healthcare | 3.8% | $89.1m | 2,850,000 | -5% | reduced |
| 8 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.7% | $87.0m | 260,000 | -9% | reduced |
| 9 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 3.4% | $78.1m | 2,100,000 | 367% | added |
| 10 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.4% | $78.0m | 800,000 | 100% | added |
| 11 | CGON CG ONCOLOGY INC | Healthcare | 3.1% | $71.0m | 1,000,000 | 74% | added |
| 12 | IRON DISC MEDICINE INC | Healthcare | 2.8% | $64.0m | 875,000 | 56% | added |
| 13 | MAZE MAZE THERAPEUTICS INC | Healthcare | 2.5% | $57.7m | 1,935,000 | 57% | added |
| 14 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.4% | $56.6m | 2,550,000 | 82% | added |
| 15 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.2% | $52.1m | 2,675,000 | 78% | added |
| 16 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.2% | $52.0m | 5,300,000 | 38% | added |
| 17 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 1.9% | $43.4m | 3,000,000 | 54% | added |
| 18 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.7% | $40.1m | 3,208,875 | 0% | held |
| 19 | BLTE BELITE BIO INC | Healthcare | 1.7% | $38.5m | 250,000 | – | new |
| 20 | ACHV ACHIEVE LIFE SCIENCE INC | 1.5% | $35.4m | 5,425,000 | – | new | |
| 21 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.5% | $35.1m | 1,880,000 | -22% | reduced |
| 22 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.5% | $34.8m | 900,000 | – | new |
| 23 | AVBP ARRIVENT BIOPHARMA INC | Healthcare | 1.5% | $34.7m | 1,000,000 | 186% | added |
| 24 | CBIO CRESCENT BIOPHARMA INC. | 1.5% | $34.2m | 1,900,000 | 294% | added | |
| 25 | CMPS COMPASS PATHWAYS PLC | Healthcare | 1.4% | $31.8m | 2,250,000 | – | new |
| 26 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.2% | $28.3m | 1,050,000 | – | new |
| 27 | REPL REPLIMUNE GROUP INC | Healthcare | 1.2% | $27.7m | 2,500,000 | – | new |
| 28 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.2% | $27.2m | 450,000 | 0% | held |
| 29 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.2% | $26.8m | 500,000 | 0% | held |
| 30 | IMVT IMMUNOVANT INC | Healthcare | 1.1% | $25.6m | 665,000 | -38% | reduced |
| 31 | JBIO JADE BIOSCIENCES INC | Healthcare | 1.1% | $25.0m | 1,125,000 | 181% | added |
| 32 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.0% | $23.6m | 465,000 | -14% | reduced |
| 33 | MANE VERADERMICS INC | Healthcare | 1.0% | $22.1m | 180,000 | 620% | added |
| 34 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.9% | $21.3m | 1,150,000 | 283% | added |
| 35 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 0.9% | $20.0m | 650,000 | -46% | reduced |
| 36 | SMMT SUMMIT THERAPEUTICS INC | Healthcare | 0.8% | $19.7m | 1,350,000 | – | new |
| 37 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.8% | $19.1m | 600,000 | -60% | reduced |
| 38 | LB PHARMACEUTICALS INC | 0.8% | $19.0m | 585,000 | -36% | reduced | |
| 39 | NERV MINERVA NEUROSCIENCES INC | 0.8% | $18.3m | 3,288,777 | 2% | added | |
| 40 | FTH FAETH THERAPEUTICS INC | 0.8% | $18.1m | 722,020 | 2307% | added | |
| 41 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 0.7% | $16.4m | 300,000 | – | new |
| 42 | DBVT DBV TECHNOLOGIES S A | 0.6% | $15.0m | 915,000 | – | new | |
| 43 | PARABILIS MEDICINES INC | 0.6% | $14.4m | 525,000 | – | new | |
| 44 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 0.6% | $13.9m | 125,000 | -72% | reduced |
| 45 | VOR VOR BIOPHARMA INC | Healthcare | 0.5% | $12.0m | 650,000 | -13% | reduced |
| 46 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 0.5% | $11.0m | 200,000 | – | new |
| 47 | IMMX IMMIX BIOPHARMA INC | 0.4% | $10.3m | 1,000,000 | -18% | reduced | |
| 48 | QTTB Q32 BIO INC | 0.4% | $10.2m | 800,000 | – | new | |
| 49 | ODYSSEY THERAPEUTICS INC | 0.4% | $9.8m | 521,736 | – | new | |
| 50 | ANNX ANNEXON INC | Healthcare | 0.4% | $8.6m | 1,500,000 | – | new |
What did Logos Global Management LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| CNTA CENTESSA PHARMACEUTICALS PLC | 16.1% | $84.4m |
| 430 TERNS PHARMACEUTICALS INC | 15.1% | $79.1m |
| CYTK CYTOKINETICS INC | 11.0% | $57.7m |
| UTHR UNITED THERAPEUTICS CORP DEL | 9.1% | $47.4m |
| MDGL MADRIGAL PHARMACEUTICALS INC | 8.5% | $44.5m |
| BIIB BIOGEN INC | 7.0% | $36.7m |
| TYRA TYRA BIOSCIENCES INC | 6.2% | $32.6m |
| NEWAMSTERDAM PHARMA COMPANY | 3.7% | $19.2m |
| MIRM MIRUM PHARMACEUTICALS INC | 3.5% | $18.5m |
| PCVX VAXCYTE INC | 3.3% | $17.4m |
| CMPX COMPASS THERAPEUTICS INC | 3.2% | $16.7m |
| JANX JANUX THERAPEUTICS INC | 2.7% | $13.9m |
| ALKS ALKERMES PLC | 2.4% | $12.4m |
| ORIC ORIC PHARMACEUTICALS INC | 2.3% | $12.0m |
| SLNOEUR SOLENO THERAPEUTICS INC | 1.6% | $8.4m |
| CRVS CORVUS PHARMACEUTICALS INC | 1.3% | $6.6m |
| MGTX MEIRAGTX HLDGS PLC | 1.2% | $6.1m |
| VSTM VERASTEM INC | 1.0% | $5.3m |
| IBIO IBIO INC | 0.5% | $2.5m |
| PHVS PHARVARIS N V | 0.4% | $1.8m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 91.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Logos Global Management LP's portfolio?
Across every quarter Logos Global Management LP has filed, its median largest position is 9.8% of the book and its median top-ten weight is 49.6%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 20.0 completed holding spells, the median lasted 1.0 quarters; 68.0 positions are still open and their final length is unknown.